BridgeBio Pharma (BBIO) Stock Analysis & AI Equity Report

Biotechnology USD Explore free reports

BridgeBio Pharma (BBIO) overview

BridgeBio Pharma (BBIO) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 502m and operating profit of USD -523m; the year-end share price was 76.49 USD and market capitalisation was USD 14,898m. BridgeBio Pharma is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get BridgeBio Pharma's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.

Key metrics & valuation multiples

Book valueUSD -2,087mFY 2025
Share price76.49 USDFY 2025 year end
RevenueUSD 502mFY 2025
Operating profitUSD -523mFY 2025
Net earningsUSD -725mFY 2025
Market capitalisationUSD 14,898mFY 2025 year end

About BridgeBio Pharma

BridgeBio is a biopharmaceutical company that discovers, develops, and commercializes medicines for genetic diseases, including conditions with significant unmet medical needs. It sells acoramidis in the United States as Attruby and markets it internationally as Beyonttra through collaboration partners and directly in some markets. The company also has approved medicines and develops therapies for patients with rare and genetically defined diseases.

Generate the BridgeBio Pharma report

BridgeBio Pharma is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.

Generate fresh report — €50.00 Delivered by email, usually within an hour

Sources & methodology

Financial figures are sourced from Valuatum's financial model for BridgeBio Pharma and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.

Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.

Analyst reports on BridgeBio Pharma

Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.